Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70^o C before use.

“It will be key to the licensing and commercialization of all our vaccine technologies.”

Advaxis has been investigating other methods for preserving its live vaccines without the need for freezing. Although live Listeria can be freeze dried, this method is associated with a loss of 90% or more of the bacterial activity. A recent test of a different method, called “foam drying” has delivered a product, which is stable at room temperature. Recovery of almost 100% of the product was observed and excellent biological activity was seen.

“This exciting work can make it possible to distribute our products to every physician’s office without special equipment using a low cost process,” commented Advaxis Chairman/CEO Thomas A. Moore. “It will be key to the licensing and commercialization of all our vaccine technologies.”